Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5568
-0.0167-2.91%
Volume:1.07M
Turnover:599.38K
Market Cap:135.30M
PE:-0.74
High:0.5904
Open:0.5800
Low:0.5505
Close:0.5735
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:3.16
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-13.02
PE(LYR):-0.31

Loading ...

Outlook Therapeutics - Pdufa Target Action Date Set for July 29, 2026

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Initiates Pre-Launch Activities for Ons-5010/Lytenava

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40

Reuters
·
Jun 04

Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase

Reuters
·
Jun 02

Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA

MT Newswires Live
·
Jun 01

Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD

Reuters
·
Jun 01

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics Prices Offering of Common Shares

MT Newswires Live
·
May 29

Outlook to sell 8.54M shares at 58.55c in registered direct offering

TIPRANKS
·
May 29

Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share

Reuters
·
May 29

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 29

Outlook Therapeutics director Yezan Munther Haddadin acquires 34,000 common shares worth $14,960

Reuters
·
May 28

Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520

Reuters
·
May 28

BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment

Reuters
·
May 26

Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava

TIPRANKS
·
May 26

Outlook Therapeutics Inc - to Resubmit Ons-5,010/Lytenava Bla in June 2026

THOMSON REUTERS
·
May 26

Outlook Therapeutics Inc - FDA Finds Substantial Evidence of Effectiveness for Lytenava in Namd

THOMSON REUTERS
·
May 26

Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review

Reuters
·
May 26

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire
·
May 26